Sarclisa (isatuximab-irfc) / ImmunoGen, AbbVie, Sanofi  >>  Phase 3
Welcome,         Profile    Billing    Logout  

31 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sarclisa (isatuximab-irfc) / Sanofi
ICARIA, NCT02990338 / 2016-003097-41: Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

Checkmark Approved in combination with pomalidomide and dexamethasone based on ICARIA-MM trial
Mar 2020 - Mar 2020: Approved in combination with pomalidomide and dexamethasone based on ICARIA-MM trial
Checkmark Submitted for 3L r/r multiple myeloma (based on ICARIA trial)
Jul 2019 - Jul 2019: Submitted for 3L r/r multiple myeloma (based on ICARIA trial)
Checkmark Submitted MAA for RRMM (based on ICARIA trial) in EU
More
Completed
3
307
Europe, Canada, Japan, US, RoW
Isatuximab, SAR650984, Sarclisa, Pomalidomide, POMALYST IMNOVID, Dexamethasone
Sanofi
Plasma Cell Myeloma
11/18
11/23
2020-004602-59: Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly diagnosed Non Frail transplant Ineligible Multiple Myeloma elderly patients (≥ 65; < 80 years).

Not yet recruiting
3
270
Europe
Isatuximab, Lenalidomide, Bortezomib, Isatuximab, Lenalidomide, Bortezomib, Solution for injection, Capsule, hard, Powder for solution for infusion, Isatuximab, Lenalidomide, Bortezomib
CHU DE POITIERS, CHU de Poitiers
Multiple Myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-005216-21: Treatment strategy adapted to residual disease: treatment of patients under 66 years of age with in Newly Diagnosed Multiple Myeloma Patients ≤66 years old and eligible for transplantation Stratégie de traitement adaptée en fonction de la maladie résiduelle : traitement de patients de moins de 66 ans, atteints de myélome multiple, nouvellement diagnostiqués et éligibles à la greffe

Not yet recruiting
3
788
Europe
Isatuximab, Iberdomide, Carfilzomib, Lenalidomide, SAR650984, CC-220, L01XX45, Concentrate for solution for infusion, Capsule, hard, Powder and solution for solution for injection, SARCLISA, KYPROLIS, REVLIMID
Intergroupe Francophone du Myélome, Intergroupe Francophone du Myélome, Sanofi Aventis, BMS/CELGENE, Amgen
Patients with multiple myeloma, newly diagnosed and eligible for autologous stem cell transplantation, patients under 66 years of age, with multiple myeloma, newly diagnosed and eligible for Autologous Stem Cells transplantation patients de moins de 66 ans, atteints de myélome multiple, nouvellement diagnostiqués et éligibles à la greffe, Diseases [C] - Cancer [C04]
 
 
IKEMA, NCT03275285 / 2017-001940-37: Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Checkmark PFS data from IKEMA trial in combination with carfilzomib and dexamethasone for 2L multiple myeloma
May 2022 - May 2022: PFS data from IKEMA trial in combination with carfilzomib and dexamethasone for 2L multiple myeloma
Checkmark Approved in Australia for multiple myeloma
May 2022 - May 2022: Approved in Australia for multiple myeloma
Checkmark Approved Sarclisa + carfilzomib for refractory multiple myeloma (based on IKEMA trial)
More
Completed
3
302
Europe, Canada, Japan, US, RoW
isatuximab SAR650984, Sarclisa, carfilzomib, Kyprolis, dexamethasone
Sanofi
Plasma Cell Myeloma
01/22
01/25
2021-002485-41: Phase 3 study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) Estudio de fase III, para evaluar la administración subcutánea frente a la intravenosa de isatuximab en combinación con pomalidomida y dexametasona en pacientes con mieloma múltiple recidivante o resistente (MMRR)

Ongoing
3
534
Europe
isatuximab, Imnovid, Dexamethasone, SAR650984, Solution for injection, Capsule, hard, Tablet, Imnovid 1mg, Imnovid 2mg, Imnovid 3mg, Imnovid 4mg, Dexamethasone 4 mg JENAPHARM®, Dexamethasone 8 mg JENAPHARM®
Sanofi-aventis recherche & developpement, Sanofi-aventis recherche & developpement
Multiple Myeloma Mieloma Múltiple, Multiple Myeloma Mieloma Múltiple, Diseases [C] - Cancer [C04]
 
 
2021-004130-11: Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D for NDMM patients who are candidates for ASCT VRD extendido más rescate temprano vs. Isatuximab-VRD vs. Isatuximab-V-Iberdomida-D en MMND candidato a TASPE

Ongoing
3
480
Europe
Iberdomide, ISATUXIMAB, LENALIDOMIDA, BORTEZOMIB, DEXAMETHASONE, CC-220, Capsule, soft, Concentrate for solution for infusion, Capsule, hard, Powder for solution for injection, Tablet, SARCLISA, REVLIMID, BORTEZOMIB TEVA, DEXAMETASONA TAD
FUNDACION PETHEMA, FUNDACION PETHEMA
Newly-diagnosed multiple myeloma (NDMM) patients who are candidates for Autologous Stem Cell Transplant (ASCT). Mieloma múltiple de nuevo diagnóstico (MMND) candidatos a trasplante autólogo de células madre hematopoyéticas (TASPE)., Newly-diagnosed multiple myeloma (NDMM) Mieloma múltiple de nuevo diagnóstico (MMND), Diseases [C] - Cancer [C04]
 
 
BENEFIT, NCT04751877 / 2024-517215-67-00 / 2020-004602-59: Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Active, not recruiting
3
270
Europe
Isatuximab, Lenalidomide, Bortezomib, Dexamethasone
Poitiers University Hospital, Intergroupe Francophone du Myelome, Sanofi
Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elderly patients
06/24
08/27
NCT06216158 / 2024-516300-41-00: Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Recruiting
3
411
Europe
Iberdomide, Isatuximab, Sarclisa, Dexamethasone
University of Heidelberg Medical Center, KKS Netzwerk, Wuerzburg University Hospital, Sanofi, Bristol-Myers Squibb
Multiple Myeloma
12/28
06/29
NCT06182774: Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Recruiting
3
570
Canada
Daratumumab, Lenalidomide, Dexamethasone, Isatuximab
Canadian Cancer Trials Group, Canadian Institutes of Health Research (CIHR), Myeloma Canada
Multiple Myeloma
01/32
07/32
IRAKLIA, NCT05405166 / 2023-508869-32-00 / 2021-002485-41 / CTR20223208: SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Hourglass Jun 2026 - Jun 2026 : Anticipated approval in US
Hourglass Jan 2025 - Jun 2025 : Regulatory submission in EU for multiple myeloma
Hourglass Jan 2025 - Jun 2025 : Regulatory submission in US for multiple myeloma
Active, not recruiting
3
531
Europe, Canada, Japan, US, RoW
Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Isatuximab, Pomalidomide Adalvo 1 mg hard capsules, MONTELUKAST , Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, DEXAMETHASONE, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM?, Dexamethason 4 mg JENAPHARM?, Pomalidomide Adalvo 4 mg hard capsules
Sanofi, Sanofi-aventis recherche & developpement
Cancer - Plasma cell myeloma recurrent
11/24
03/27
MIDAS, NCT04934475 / 2024-513889-19-00 / 2020-005216-21: MInimal Residual Disease Adapted Strategy

Active, not recruiting
3
791
Europe, RoW
Kyprolis 60 mg powder for solution for infusion, Revlimid 5 mg hard capsules, Iberdomide, Revlimid 25 mg hard capsules, SARCLISA 20mg/mL concentrate for solution for infusion., Neofordex 40 mg tablets, DECTANCYL 0,5 mg, comprim?, Revlimid 10 mg hard capsules, Isatuximab
Intergroupe Francophone du Myelome, BMS/CELGENE, Sanofi Aventis, Amgen, Intergroupe Francophone du My?lome
Multiple Myeloma
09/24
09/28
GMMG-HD7, NCT03617731 / 2017-004768-37: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Jan 2025 - Dec 2025: From GMMG HD7 trial for newly diagnosed multiple myeloma
Hourglass Jan 2025 - Jun 2025 : Regulatory submission in US for 1L TE MM
Hourglass Oct 2021 - Dec 2021 : From first part of trial in newly diagnosed multiple myeloma
Active, not recruiting
3
662
Europe
Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Isatuximab
University of Heidelberg Medical Center
Multiple Myeloma
06/28
06/28
IsKia, NCT04483739 / 2019-004844-32: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation ( TRIAL)

Active, not recruiting
3
302
Europe, RoW
Carfilzomib Lenalidomide Dexamethasone, KRd, Isatuximab Carfilzomib Lenalidomide Dexamethasone, Isa-KRD
European Myeloma Network B.V., EMN Trial Office S.r.l. Impresa Sociale, Sanofi, Amgen
Multiple Myeloma
07/25
12/32
IMROZ, NCT03319667 / 2024-514417-34-00 / 2017-002238-21 / CTR20180937: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Jan 2024 - Dec 2024: Submission for newly diagnosed multiple myeloma (based on IMROZ trial)
Hourglass Oct 2023 - Dec 2023 : Pivotal data readout from IMROZ trial for 1L multiple myeloma
Hourglass Oct 2021 - Mar 2022 : Regulatory submissions for NDMM (based on IMROZ trial) in EU
Hourglass Jan 2021 - Dec 2021 : Primary data from IMROZ trial for newly diagnosed multiple myeloma
Active, not recruiting
3
475
Europe, Japan, US, RoW
Isatuximab SAR650984, Sarclisa, Bortezomib, Velcade®, Lenalidomide, Dexamethasone
Sanofi
Cancer
04/27
06/27
GEM21menos65, NCT05558319: NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Recruiting
3
480
Europe
Bortezomib, Isatuximab, Iberdomide, Lenalidomide, Dexamethasone
PETHEMA Foundation, Bristol-Myers Squibb, Sanofi, Adknoma Health Research
Newly Diagnosed Multiple Myeloma
04/27
04/29
AlloRelapseMM, NCT05675319 / 2024-510590-14-00 / 2021-001005-67: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Terminated
3
28
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/25
03/25
ITHACA, NCT04270409 / 2023-507419-37-00 / 2019-003139-47 / CTR20201825: Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Active, not recruiting
3
337
Europe, Canada, Japan, US, RoW
Isatuximab SAR650984, Sarclisa, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent
Sanofi
Plasma Cell Myeloma
10/30
10/33
2019-001258-25: A phase II and phase III trial comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplant (TE)

Ongoing
2/3
1400
Europe
Isatuximab, Revlimid (Lenalidomide), Cyclophosphamide, Dexamethasone, Bortezomib, L04AX04, Solvent for solution for infusion, Capsule, hard, Tablet, Solution for injection, Kyprolis, Revlimid (Lenalidomide), Cyclophosphamide, Dexamethasone, Bortezomib
University of Leeds, Cancer Research UK, Sanofi S.A, Celgene Corporation
Newly diagnosed multiple myeloma, Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
NCT07732712: Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells

Not yet recruiting
2/3
15
NA
Isatuximab, VRD
The Affiliated People's Hospital of Ningbo University
Multiple Myeloma
08/28
12/28
IFM2020-05-BENEFIT, 2024-517215-67-00`2020-004602-59: -Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elderly patients (? 65; < 80 years).

Recruiting
2/3
270
Europe
SARCLISA 20mg/mL concentrate for solution for infusion., DEXAMETHASONE, VELCADE 3.5 mg powder for solution for injection, Revlimid 25 mg hard capsules
Centre Hospitalier Universitaire De Poitiers, CHU de Poitiers, SANOFI
Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elderly patients
 
 
GMMG-HD7, 2024-513464-26-00: A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma

Active, not recruiting
2/3
662
Europe
Lenalidomide, DEXAMETHASONE, VELCADE 3.5 mg powder for solution for injection, Isatuximab
Universitaetsklinikum Heidelberg A, Bristol Myers Squibb (Celgene), Sanofi-Aventis Deutschland GmbH
Multiple Myeloma
 
 
EFC12522, 2024-514417-34-00: A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Active, not recruiting
2/3
308
Europe
Isatuximab, VELCADE 3.5 mg powder for solution for injection, Dexamethasone 3.3 mg/ml solution for injection, Revlimid 10 mg hard capsules, Revlimid 25 mg hard capsules, DexaGalen? 8 mg injekt Injektionsl?sung, Revlimid 15 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethason 4 mg JENAPHARM?, Zelvina 20 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 10 mg hard capsules, Zelvina 25 mg hard capsules
Sanofi-Aventis Recherche & Developpement
Cancer
 
 
ELIAS, NCT05665140 / 2022-500453-16-00: Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Recruiting
2/3
100
Europe
Isatuximab, Sarclisa®, Lenalidomide, Lenalidomid®, Bortezomib, Velcade®, Dexamethasone, autologous stem cell transplant
University Hopsital Schleswig Holstein Campus Lübeck, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Deutschland GmbH
Newly Diagnosed Multiple Myeloma
08/27
10/28
MIDAS:IFM 2020-02, 2024-513889-19-00`2020-005216-21: MInimal residual Disease Adapted Strategy / IFM 2020-02

Not yet recruiting
2/3
791
Europe
Kyprolis 60 mg powder for solution for infusion, Iberdomide, Revlimid 25 mg hard capsules, SARCLISA 20mg/mL concentrate for solution for infusion., Isatuximab, Revlimid 10 mg hard capsules, Neofordex 40 mg tablets, Revlimid 5 mg hard capsules, DECTANCYL 0,5 mg, comprim
Intergroupe Francophone Du Myelome, Sanofi Aventis, Intergroupe Francophone du My?lome, Amgen, BMS/CELGENE
Multiple Myeloma
 
 
GEM21menos65, 2024-517008-12-00`2021-004130-11: Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT

Active, not recruiting
2/3
480
Europe
Revlimid 15 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Isatuximab, Iberdomide, Revlimid 10 mg hard capsules, ISATUXIMAB, Revlimid 5 mg hard capsules, Revlimid 25 mg hard capsules, DEXAMETHASONE
Fundacion PETHEMA, FUNDACION PETHEMA
Newly-diagnosed multiple myeloma (NDMM)
 
 
GMMG-HD9/DSMM XVIII, 2023-507402-13-00: A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (-trial)

Recruiting
2/3
451
Europe
Dexamethason TAD? 20 mg Tabletten, Iberdomide, Isatuximab
Universitaetsklinikum Heidelberg A, Bristol Myers Squibb, Sanofi-Aventis Deutschland GmbH
Multiple myeloma
 
 
EMN24, 2024-513422-38-00: A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenalidomide-Dexamethasone in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL)

Active, not recruiting
2/3
302
Europe
SOLDESAM 0,2% gocce orali, soluzione, Revlimid 20 mg hard capsules, Revlimid 25 mg hard capsules, ISATUXIMAB, Revlimid 15 mg hard capsules, Dexsol 2mg/5ml Oral Solution, Revlimid 10 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Revlimid 5 mg hard capsules
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
Newly diagnosed multiple myeloma
 
 
EFC15992, 2023-507419-37-00: Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma

Active, not recruiting
2/3
272
Europe
Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Zelvina 15 mg hard capsules, Dexamethason 8 mg JENAPHARM?, Dexamethason 4 mg JENAPHARM?, DexaGalen? 8 mg injekt Injektionsl?sung
Sanofi-Aventis Recherche & Developpement
Plasma cell myeloma
 
 
AlloRelapseMMStudy, 2024-510590-14-00`2021-001005-67: Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy

Completed
2/3
400
Europe
Imnovid 3 mg hard capsules, Imnovid 2 mg hard capsules, SARCLISA 20mg/mL concentrate for solution for infusion., Empliciti 400 mg powder for concentrate for solution for infusion., Revlimid 5 mg hard capsules, Fortecortin? Inject 8 mg Injektionsl?sung in einer Ampulle, Fortecortin? Inject 40 mg Injektionsl?sung in einer Ampulle, Fortecortin? Inject 4 mg Injektionsl?sung in einer Ampulle, Fortecortin? 8 mg Tabletten, DARZALEX 20 mg/mL concentrate for solution for infusion, NEXPOVIO 20 mg film-coated tablets, NINLARO 4 mg hard capsules, Fortecortin? 4 mg Tabletten, Fortecortin? 2 mg Tabletten, Fortecortin? Inject 100 mg Injektionsl?sung in einer Ampulle, Revlimid 10 mg hard capsules, Fortecortin? 0,5 mg Tabletten, Imnovid 1 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, Empliciti 300 mg powder for concentrate for solution for infusion., Kyprolis 60 mg powder for solution for infusion, NINLARO 3 mg hard capsules, Bortezomib medac 3,5 mg Pulver zur Herstellung einer Injektionsl?sung, Kyprolis 30 mg powder for solution for infusion, NINLARO 2.3 mg hard capsules
University Medical Center Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA)
multiple myeloma
 
 
2024-511437-35-00: GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults with Acute Lymphoblastic Leukemia

Recruiting
2/3
1100
Europe
SARCLISA 20mg/mL concentrate for solution for infusion., BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., Iclusig 15 mg film-coated tablets
Assistance Publique Hopitaux De Paris, INCYTE, SANOFI, [DGOS-INCA] : PHRC-K20-100, AMGEN
Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.
 
 
GRAAL-2024, NCT06860269 / 2024-511437-35-00: A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

Recruiting
2/3
1200
Europe
Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone, Randomization + Blinatumomab + Ponatinib + chemotherapy, Randomization 1 + Allo HSCT, Randomization 2 + Allo HSCT
Assistance Publique - Hôpitaux de Paris, AMGEN, SANOFI, INCYTE, [DGOS-INCA] : PHRC-K20-100
Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.
03/35
03/35

Download Options